Leap Therapeutics Q2 2024 Earnings Report
Key Takeaways
Leap Therapeutics reported a net loss of $20.4 million for the second quarter of 2024, compared to a net loss of $13.4 million for the same period in 2023. Research and development expenses increased to $17.9 million, driven by higher clinical trial costs. Cash and cash equivalents totaled $78.5 million at the end of the quarter.
Net loss for Q2 2024 was $20.4 million, compared to $13.4 million in Q2 2023.
Research and development expenses increased to $17.9 million, driven by clinical trial costs.
General and administrative expenses decreased to $3.4 million from $3.6 million in the same period last year.
Cash and cash equivalents totaled $78.5 million as of June 30, 2024.
Leap Therapeutics
Leap Therapeutics
Forward Guidance
Leap Therapeutics is positioned to achieve critical company milestones with the momentum provided by a $40 million private placement. Initial data from two randomized controlled studies are expected over the next 12 months.